2021-01-08,InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
2021-01-08,InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
2021-01-05,InMed to Participate at Virtual Conferences in January 2021
2021-01-05,InMed to Participate at Virtual Conferences in January 2021
2020-12-11,"/R E M I N D E R -- Media Advisory - Prime Minister's itinerary for Friday, December 11, 2020/"
2020-12-03,InMed Licenses MiDROPSÂ® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
2020-11-25,InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
2020-11-24,InMed Announces Election of Directors
2020-11-18,InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
2020-11-18,InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
2020-11-17,Lonely Planet's Best in Travel Picks for 2021 Reflect a New World for Travel
2020-11-16,InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
2020-11-13,InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
2020-11-12,IIROC Trade Resumption - IN
2020-11-12,"InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol ""INM"""
2020-11-12,"InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol ""INM"""
2020-11-12,IIROC Trading Halt - IN
